media – Page 6 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Kangtai Biological’s revenue in the first quarter of 2025 increased by more than 40% year-on-year, and multiple projects such as the pentavalent vaccine made significant progress

The evening of April 20, Kangtai Biological (300601) released its 2024 annual report and 2025 first quarter report. The company achieved operating income of 2.652 billion yuan in 2024 and a net profit of 246 million yuan attributable to the parent company after deducting non-recurring items; operating income in the first quarter of 2025 was 645 million yuan, a year-on-year increase of 42.85%; net profit attributable to the parent company after deducting non-recurring items was 17 million yuan, a year-on-year increase of 17.56%. The annual report shows that Kangtai Biological’s R&D investment in 2024 was 569 million yuan, accounting for 21.47% of the operating income of the year, and the cumulative R&D investment in the past three years was 2.105 billion yuan, accounting for 22.67% of the cumulative operating income in the past three years. During the reporting period, Kangtai Biological’s new vaccine R&D pipeline has made a number of ...
- Source: drugdu
- 88
- April 21, 2025
The national immunization program will enter a period of dynamic adjustment, and many new vaccines are expected to be included

On the morning of April 19, the 2025 Vaccine and Health Conference was held. Shen Hongbing, deputy director of the National Health Commission and director of the National Disease Control Bureau, shared his outlook and ideas on the future adjustment model of the national immunization program in his speech. Shen Hongbing said that one direction in the future is to dynamically adjust and optimize the national immunization program strategy, and optimize it according to the principles of overall planning, dynamic adjustment, and step-by-step implementation. “We are preparing to make a five-year plan,” he said. The future goal is to gradually narrow the gap between the domestic immunization program and the international level, and gradually include vaccines that need to be included. The last time China substantially included a new vaccine was in 2007. The adjustments in recent years mainly involve vaccination procedures and strategies. Therefore, there is a gap between ...
- Source: drugdu
- 103
- April 21, 2025
Beike Biotech’s revenue and net profit both fell, sales of herpes zoster vaccines decreased, and the core of marketing left

On the evening of April 20, Beike Biotech (688276) released its 2024 annual report showing that during the reporting period, the company’s operating income was approximately 1.229 billion yuan, a year-on-year decrease of 32.64%; the corresponding attributable net profit was approximately 232 million yuan, a year-on-year decrease of 53.67%. It is planned to pay a cash dividend of 1.69 yuan (including tax) per 10 shares to all shareholders. In this regard, the annual report pointed out that the main reason was the decrease in revenue and net profit due to the decrease in sales of herpes zoster vaccines during the reporting period; the net cash flow generated by operating activities was 406.5022 million yuan, 255.2070 million yuan in the same period last year, an increase of 59.28%, mainly due to the increase in sales proceeds; basic earnings per share, diluted earnings per share, basic earnings per share after deducting non-recurring ...
- Source: drugdu
- 84
- April 21, 2025
High incidence recently, no vaccine to prevent! Guangdong reports 1542 cases of scarlet fever

Recently, the number of cases of scarlet fever in Guangdong, Hunan and other places has increased. In the absence of an effective vaccine, how to correctly understand scarlet fever and scientifically prevent it has received high attention. On April 14, the Guangdong Provincial Disease Control and Prevention Bureau announced the provincial statutory infectious disease epidemic situation in March 2025. Among them, the number of scarlet fever cases reported in Guangdong Province in March was 1542, an increase of 641 cases from February. On April 17, Hu Yan, deputy director of the Children’s Medical Center of the First Affiliated Hospital of Hunan University of Chinese Medicine, said that the number of children with scarlet fever seen in the hospital’s pediatric outpatient and emergency departments has increased recently. “This year’s spring in the south is relatively dry, which is conducive to the survival and spread of group A hemolytic streptococci.” On April ...
- Source: drugdu
- 84
- April 21, 2025
【EXPERT Q&A】Medical devices have high requirements for the stability and safety of PCBA. What are the key control points in the development and production process?

Drugdu.com expert’s response: In the research, development, and production process of Printed Circuit Board Assembly (PCBA) for medical devices, stability and safety are core requirements. To ensure that products meet the high standards of the medical industry, strict controls must be implemented across multiple dimensions, including design, materials, manufacturing processes, testing, regulatory compliance, and supply chain management. The following is a detailed analysis of key control points: I. Design Phase Functional Safety Design Employ redundant design, fail-safe mechanisms, and fault-tolerant design to ensure that a single failure does not lead to system failure. Conduct risk analysis (e.g., FMEA, FTA) to identify potential failure modes and develop mitigation measures. Electromagnetic Compatibility (EMC) Design Optimize circuit layout to reduce electromagnetic interference (EMI) and radio frequency interference (RFI). Select low-emission components and incorporate shielding and filtering designs to ensure stable operation in complex electromagnetic environments. Thermal Design and Reliability Assessment Analyze key component ...
- Source: drugdu
- 78
- April 21, 2025
【EXPERT Q&A】What problems should domestic pharmaceutical and medical equipment enterprises pay attention to in export?

Drugdu.com expert’s response: When domestic pharmaceutical and medical device enterprises engage in foreign trade exports, they need to focus on core issues such as policy regulations, market demand, product quality, certification and compliance, and branding and after-sales service to ensure the smooth progress of export business. Below are specific considerations: I. Policy Regulations and Compliance Requirements Target Market Regulations Different countries have significantly varying regulatory standards for medical devices. For example, the EU requires compliance with CE certification and MDR regulations, while the US requires FDA 510(k) registration or PMA approval. Enterprises must understand the regulatory requirements of the target market in advance to avoid product rejection due to compliance issues. Domestic Export Policies Enterprises need to obtain medical device registration certificates and production licenses issued by the National Medical Products Administration (NMPA) and handle import-export business licenses. Special medical devices (such as COVID-19 testing reagents) may require additional export ...
- Source: drugdu
- 59
- April 18, 2025
Weixinkang’s wholly-owned subsidiary obtains approval for clinical trial of succinylated gelatin injection

April 16, Weixinkang(603676) issued an announcement that its wholly-owned subsidiary Baiyi Pharmaceutical recently received the “Drug Clinical Trial Approval Notice” for Succinylated Gelatin Electrolyte Sodium Acetate Injection approved and issued by the National Medical Products Administration. The drug is an injection with a specification of 500 mg, and the application is for clinical trials. The approval conclusion shows that the clinical trial application for succinylated gelatin electrolyte sodium acetate injection meets the relevant requirements for drug registration and is approved for clinical trials. As of March 2025, the company’s cumulative R&D investment in this drug is approximately RMB 3.15 million. As a colloidal plasma volume substitute, succinylated gelatin electrolyte sodium acetate injection is mainly used for the treatment of hypovolemia and shock, and can be used in combination with crystalloid solutions. The announcement also mentioned that B. Braun Medical’s similar drug has been approved for marketing, and five other companies ...
- Source: drugdu
- 57
- April 18, 2025
The first treatment guideline for Asian pancreatic cancer patients was released, and therapeutic vaccines also officially entered the clinic

On April 15, 2025, during the National Cancer Prevention and Treatment Publicity Week, the international authoritative journal “European Society for Medical Oncology Gastrointestinal Oncology” officially released the “Asian Expert Consensus on Systemic Treatment of Pancreatic Cancer” (hereinafter referred to as “Asian Consensus”), filling the gap in the previous Asian pancreatic cancer diagnosis and treatment standards. As the core developer of the Asian consensus, Professor Shen Baiyong, Vice President of Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine and Director of the Pancreatic Disease Center, told the reporter of China Business News: “This important achievement demonstrates China’s global influence in the field of pancreatic cancer diagnosis and treatment, and marks that Asian pancreatic cancer diagnosis and treatment has entered a new stage. We have not only solved key problems in clinical practice, but also let the international academic community hear the strong voice from Asia.” Although there have been ...
- Source: drugdu
- 109
- April 17, 2025
The first influenza vaccine bidding this year was announced, and each shot costs only 10 yuan

On April 14, according to the Shenzhen Government Procurement Network, the Shenzhen Center for Disease Control and Prevention announced the results of the city’s influenza vaccination project for people aged 60 and above. Hualan Vaccine (full name “Hualan Biological Vaccine Co., Ltd.”) won the bid for the trivalent influenza vaccine at 10 yuan per shot. It is understood that this is also the first influenza vaccine bidding project in the country this year. In recent years, the winning bid price of public influenza vaccines has declined significantly, and the winning bid price of products has occurred several times at about 10 yuan per shot. Interface News previously reported that in October last year, Beijing Kexing’s trivalent influenza vaccine won the bid at a price of 10.5 yuan per shot. At that time, Fosun Yalifeng, which participated in the same bidding, quoted as low as 6.5 yuan per shot. In September ...
- Source: drugdu
- 97
- April 17, 2025
Obtained Korean Drug Registration Certificate

On April 15, Tonghe Pharmaceutical announced that the company recently received the drug registration certificate for Asartan Potassium issued by the Korean Ministry of Food and Drug Safety. The manufacturer’s name is Jiangxi Tonghe Pharmaceutical Co., Ltd., the manufacturer’s address is Fengxin High-tech Industrial Park, Jiangxi Province, the certification scope is Asartan Potassium API, the certificate number is 2025-A1-0844, and the issuance date is 2025.04.14. Asartan Potassium is suitable for the treatment of primary hypertension in adults. The company’s Asartan Potassium product has obtained the Korean Drug Registration Certificate, which means that the company’s Asartan Potassium API has obtained access to the Korean market, which will play a positive role in the company’s further expansion of international market business. https://finance.eastmoney.com/a/202504153377409386.html
- Source: drugdu
- 87
- April 17, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.